Brent Johnson Sells 3,000 Shares of Iradimed Corp (NASDAQ:IRMD) Stock

Iradimed Corp (NASDAQ:IRMD) VP Brent Johnson sold 3,000 shares of the business’s stock in a transaction dated Wednesday, June 12th. The shares were sold at an average price of $20.57, for a total transaction of $61,710.00. Following the completion of the sale, the vice president now owns 2,368 shares of the company’s stock, valued at approximately $48,709.76. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link.

Brent Johnson also recently made the following trade(s):

  • On Monday, June 10th, Brent Johnson sold 1,000 shares of Iradimed stock. The stock was sold at an average price of $20.06, for a total transaction of $20,060.00.
  • On Friday, June 7th, Brent Johnson sold 1,000 shares of Iradimed stock. The shares were sold at an average price of $20.00, for a total transaction of $20,000.00.
  • On Thursday, May 23rd, Brent Johnson sold 4,000 shares of Iradimed stock. The stock was sold at an average price of $21.78, for a total transaction of $87,120.00.
  • On Monday, May 20th, Brent Johnson sold 2,000 shares of Iradimed stock. The shares were sold at an average price of $22.53, for a total transaction of $45,060.00.
  • On Friday, May 17th, Brent Johnson sold 3,000 shares of Iradimed stock. The stock was sold at an average price of $21.83, for a total transaction of $65,490.00.

NASDAQ IRMD traded down $0.08 on Friday, reaching $20.59. The company had a trading volume of 1,862 shares, compared to its average volume of 48,697. The stock has a market cap of $234.08 million, a PE ratio of 47.88 and a beta of 1.78. The company has a quick ratio of 8.63, a current ratio of 9.48 and a debt-to-equity ratio of 0.06. Iradimed Corp has a 1 year low of $18.45 and a 1 year high of $38.78.

Iradimed (NASDAQ:IRMD) last issued its earnings results on Tuesday, April 30th. The medical equipment provider reported $0.11 earnings per share for the quarter, hitting the Thomson Reuters’ consensus estimate of $0.11. The firm had revenue of $8.44 million for the quarter, compared to analyst estimates of $8.38 million. Iradimed had a return on equity of 13.98% and a net margin of 23.00%. Sell-side analysts anticipate that Iradimed Corp will post 0.64 EPS for the current fiscal year.

IRMD has been the subject of several recent research reports. BidaskClub raised shares of Iradimed from a “hold” rating to a “buy” rating in a research note on Tuesday, March 26th. ValuEngine cut shares of Iradimed from a “buy” rating to a “hold” rating in a report on Wednesday, May 1st. Finally, Zacks Investment Research upgraded shares of Iradimed from a “hold” rating to a “buy” rating and set a $28.00 price objective on the stock in a research report on Tuesday, May 7th. Two analysts have rated the stock with a hold rating and two have given a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and an average price target of $31.50.

A number of institutional investors have recently made changes to their positions in the stock. Barclays PLC raised its stake in shares of Iradimed by 53.9% during the 4th quarter. Barclays PLC now owns 2,059 shares of the medical equipment provider’s stock worth $50,000 after purchasing an additional 721 shares in the last quarter. GSA Capital Partners LLP grew its holdings in shares of Iradimed by 14.6% during the 4th quarter. GSA Capital Partners LLP now owns 11,796 shares of the medical equipment provider’s stock worth $289,000 after purchasing an additional 1,500 shares in the last quarter. JPMorgan Chase & Co. boosted its stake in Iradimed by 4.3% in the 1st quarter. JPMorgan Chase & Co. now owns 37,122 shares of the medical equipment provider’s stock valued at $1,043,000 after buying an additional 1,518 shares in the last quarter. Geode Capital Management LLC raised its position in Iradimed by 3.8% in the 4th quarter. Geode Capital Management LLC now owns 45,822 shares of the medical equipment provider’s stock valued at $1,120,000 after purchasing an additional 1,690 shares during the last quarter. Finally, Strs Ohio raised its position in shares of Iradimed by 14.5% during the fourth quarter. Strs Ohio now owns 18,700 shares of the medical equipment provider’s stock worth $457,000 after acquiring an additional 2,367 shares during the last quarter. 23.53% of the stock is owned by hedge funds and other institutional investors.

WARNING: This report was originally posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this report on another site, it was illegally copied and reposted in violation of US and international trademark and copyright law. The correct version of this report can be viewed at https://www.dispatchtribunal.com/2019/06/14/brent-johnson-sells-3000-shares-of-iradimed-corp-nasdaqirmd-stock.html.

About Iradimed

IRADIMED CORPORATION develops, manufactures, markets, and distributes magnetic resonance imaging (MRI) compatible medical devices, and related accessories and services in the United States and internationally. It offers MRI compatible intravenous (IV) infusion pump system with associated disposable IV tubing sets; and MRI compatible patient vital signs monitoring system.

Featured Story: Call Option

Insider Buying and Selling by Quarter for Iradimed (NASDAQ:IRMD)

Receive News & Ratings for Iradimed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iradimed and related companies with MarketBeat.com's FREE daily email newsletter.